Aminophylline dihydrate
Based on 3 publication(s) in Google Scholar
Aminophylline Dihydrate is a competitive phosphodiesterase 3/4 (PDE3/4) inhibitor. Aminophylline Dihydrate also acts as an adenosine receptor (adenosine receptor) antagonist. Aminophylline Dihydrate elevates intracellular cAMP levels via competitive inhibition of PDE3 and PDE4, antagonizes the adenosine A1 receptor (ADORA1, regulates intracellular calcium signal transduction and synaptic vesicle recycling, upregulates the PPAR signaling pathway, and downregulates the glutamatergic synaptic pathway simultaneously. Aminophylline Dihydrate can be used in research related to major depressive disorder, epilepsy, asthma, and chronic obstructive pulmonary disease (COPD).
For research use only. We do not sell to patients.
- CAS No.: 56440-60-9
- Formula: C7H8N4O2·1/2C2H8N2·2H2O
- Molecular Weight:246.25
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Aminophylline dihydrate
MoreAll Adenosine Receptor Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
PDE3 |
PDE4 |
In Vitro
In Vivo
Aminophylline (50-100 mg/kg; i.p.; single administration; treatment 30 min prior to electroshock test) Dihydrate potently reduces the anti-electroconvulsive efficacy of most tested antiepileptic drugs in mice[2].
Aminophylline (7 mg/kg loading dose + 1.5 mg/kg/hr maintenance dose; i.v.; single continuous infusion; duration ≥ 1.5 h) Dihydrate increases minute ventilation, tidal volume, respiratory rate, parasternal muscle shortening, minute integrated electromyographic activity of the parasternal muscle, and parasternal muscle contractility in awake healthy dogs, while it does not alter tidal electromyographic activity and baseline muscle length of the parasternal muscle[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (male, 7 weeks old, 20-25 g, chronic restraint stress-induced depressive-like behavior)[1]
-
Dosage:5 mg/kg; 10 mg/kg; 20 mg/kg
-
Administration:i.p.; daily; 15 days
-
Result:Attenuated depressive-like behavior in a dose-dependent manner.
Reduced immobility time significantly in the tail suspension test (TST) and forced swimming test (FST).
Increased total grooming time significantly in the sucrose splash test (SST).
-
Animal Model:Albino Swiss (male, 20-25 g, maximal electroconvulsions induced via corneal electrodes with 50 Hz alternating current for 0.2 s)[2]
-
Dosage:50 mg/kg; 100 mg/kg
-
Administration:i.p.; sigle dose; 30 min before electroconvulsion test
-
Result:Decreased the anticonvulsant efficacy of diazepam, diphenylhydantoin, phenobarbital, and valproate markedly.
Showed less effectiveness in reducing the action of carbamazepine and was inactive against acetazolamide.
-
Animal Model:Mongrel (young adult male, mean weight 30.6 kg, chronically implanted with sonomicrometry crystals and fine-wire EMG electrodes in the parasternal muscle)[6]
-
Dosage:7 mg/kg (loading dose); 1.5 mg/kg/hr (continuous infusion)
-
Administration:i.v.; single continuous infusion; data were recorded at least 1.5 hours after the start of drug administration
-
Result:Increased minute ventilation, tidal volume, and respiratory frequency significantly during resting and hypercapnic stimulated breathing.
Increased parasternal muscle shortening significantly without a corresponding increase in EMG activity.
Increased parasternal muscle contractility significantly.
Chemical Information
-
CAS No. 56440-60-9
-
Molecular Weight 246.25
-
Formula C7H8N4O2·1/2C2H8N2·2H2O
-
SMILES
O=C(N1C)N(C)C2=C(N=CN2)C1=O.NCCN.[1/2].O.O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
-
Biol Proced Online
Establishment of a mouse lung cancer organoid model and its applications for therapeutic screening. [Abstract]2025 Jun 16;27(1):21. PMID: 40524168 -
3 Biotech
Triple regulation of oxidative-acetylation cycling pathways in COPD glucocorticoid resistance by HuaTanJiangQi capsules. [Abstract]2025 Apr;15(4):72. PMID: 40060290
Purity & Documentation
References
[1]. Samante FI, et al. Potential antidepressant properties of aminophylline in male mice exposed to chronic restraint stress. Pharmacological reports : PR. 2026 Jun;78(3):748-761. [Content Brief]
[2]. Czuczwar SJ, et al. Effect of aminophylline on the protective action of common antiepileptic drugs against electroconvulsions in mice. Epilepsia. 1986;27(3):204-8. [Content Brief]
[3]. Mengozzi G, et al. Comparative bioavailability of two sustained-release theophylline formulations in the dog. Pharmacological research. 1998 Dec;38(6):481-5. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)